MAPT and Alzheimer disease: We used an unbiased ranking approach to prioritize 19 predicted key drivers for in vitro experimentation and tested the effects of their knockdown on the central components of the pathological hallmarks of AD, Aβ peptides (Aβ38, Aβ40, Aβ42) and phosphorylated tau protein, in a human iN system.